SCHEMBL15034086

SCHEMBL15034086

CCOc1cccc(C(=O)N2CCN(C(=O)c3ncn(-c4cccc(Cl)c4)n3)C(C)(C)C2)n1

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
KCNK3 O14649 1/20 0.41
KCNK9 Q9NPC2 1/20 0.41
MAPT P10636 3/20 0.40
POLB P06746 1/20 0.40
MGLL Q99685 4/20 0.39
LMNA P02545 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
TSHR P16473 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
IRAK4 Q9NWZ3 1/20 0.38
SLC6A7 Q99884 1/20 0.36
ALDH1A1 P00352 2/20 0.36
GRM5 P41594 2/20 0.35
HRH3 Q9Y5N1 1/20 0.35
CFTR P13569 1/20 0.34
CCKAR P32238 1/20 0.34
GAA P10253 1/20 0.34
TP53 P04637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15034041 0.92 GRM5 (0.39) KCNK3KCNK9MAPTPOLBMGLL
SCHEMBL15019975 0.90 GRM5 (0.41) KCNK3KCNK9MAPTPOLBMGLL
SCHEMBL15034062 0.87 GRM5 (0.47) MAPTPOLBMGLLLMNASMN1; SMN2
SCHEMBL15034076 0.87 SLC6A7 (0.39) MAPTPOLBMGLLSLC6A7GRM5
SCHEMBL15019498 0.86 GRM5 (0.39) MAPTPOLBMGLLIRAK4SLC6A7
SCHEMBL15034063 0.86 MGLL (0.38) MAPTPOLBMGLLSLC6A7GRM5
SCHEMBL15034042 0.86 GRM5 (0.40) KCNK3KCNK9MAPTPOLBMGLL
SCHEMBL15034045 0.85 KCNK3 (0.40) KCNK3KCNK9MAPTPOLBMGLL
SCHEMBL15034038 0.84 MGLL (0.40) MAPTPOLBMGLLIRAK4SLC6A7
SCHEMBL15034033 0.84 MGLL (0.39) MAPTPOLBMGLLSMN1; SMN2NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-8883789-B2 Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-11 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed
US-20130158042-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158042-A1 NOVEL COMPOUNDS GRM5, GRIK5, GRM1 KCNK3 1154/4885KCNK9 1745/4885MAPT 270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.